Fishman Jay A LTD Arcutis Biotherapeutics, Inc. Transaction History

Fishman Jay A LTD

$1.01 Billion
Q3 2024

A detailed history of Fishman Jay A LTD transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Fishman Jay A LTD holds 418,000 shares of ARQT stock, worth $3.94 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares

418,000

Previous 346,600 20.6%

Holding current value

$3.94 Million

Previous $3.22 Million 20.6%

% of portfolio

0.39%

Previous 0.34%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$8.32 - $11.0 $594,048 - $785,400	71,400 Added 20.6%	418,000 $3.89 Million
Q2 2024 Aug 05, 2024	BUY	$7.24 - $12.53 $2.41 Million - $4.17 Million	332,566 Added 2369.72%	346,600 $3.22 Million
Q2 2024 Jul 31, 2024	SELL	$7.24 - $12.53 $1.52 Million - $2.63 Million	-210,266 Reduced 93.74%	14,034 $130,000
Q1 2024 Apr 23, 2024	BUY	$3.25 - $11.77 $556,725 - $2.02 Million	171,300 Added 323.21%	224,300 $2.22 Million
Q4 2023 Jan 24, 2024	BUY	$1.84 - $4.82 $97,520 - $255,460	53,000 New	53,000 $171,000
Q3 2023 Nov 13, 2023	BUY	$5.31 - $10.98 $53,099 - $109,800	10,000 Added 12.99%	87,000 $461,000
Q2 2023 Aug 15, 2023	BUY	$7.51 - $15.0 $99,132 - $198,000	13,200 Added 20.69%	77,000 $733,000
Q1 2023 May 09, 2023	BUY	$10.23 - $17.14 $204,600 - $342,800	20,000 Added 45.66%	63,800 $701,000
Q4 2022 Feb 13, 2023	SELL	$13.96 - $20.4 $41,880 - $61,199	-3,000 Reduced 6.41%	43,800 $648,000
Q3 2022 Oct 26, 2022	BUY	$17.85 - $26.95 $460,530 - $695,310	25,800 Added 122.86%	46,800 $894,000
Q2 2022 Aug 09, 2022	BUY	$16.33 - $22.2 $342,929 - $466,200	21,000 New	21,000 $447,000

Others Institutions Holding ARQT

# of Institutions

197

Shares Held

129M

Call Options Held

738K

Put Options Held

82K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $568M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fishman Jay A LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fishman Jay A LTD with notifications on news.

Account